BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33104298)

  • 1. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
    Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
    Kuempers C; van der Linde LIS; Reischl M; Vogel W; Stellmacher F; Reck M; Heigener D; Rabe KF; Kirfel J; Perner S; Welker L
    Virchows Arch; 2020 Feb; 476(2):261-271. PubMed ID: 31392467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
    Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
    Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
    Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Chen F; Zhou F; Xia Y; Zhong J; Moreira AL; Simms A; Sun W; Wei XJ; Simsir A
    Am J Clin Pathol; 2020 Sep; 154(4):517-524. PubMed ID: 32589185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
    Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.